RT Journal Article
SR Electronic
T1 <em>TPX2</em> and <em>AURKA</em> promote 20q amplicon-driven colorectal adenoma to carcinoma progression
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 1568
OP 1575
DO 10.1136/gutjnl-2011-301153
VO 61
IS 11
A1 Sillars-Hardebol, Anke H
A1 Carvalho, Beatriz
A1 Tijssen, Marianne
A1 Beliën, Jeroen A M
A1 de Wit, Meike
A1 Delis-van Diemen, Pien M
A1 Pontén, Fredrik
A1 van de Wiel, Mark A
A1 Fijneman, Remond J A
A1 Meijer, Gerrit A
YR 2012
UL http://gut.bmj.com/content/61/11/1568.abstract
AB Background and objective Progression of a colorectal adenoma to invasive cancer occurs in a minority of adenomas and is the most crucial step in colorectal cancer pathogenesis. In the majority of cases, this is associated with gain of a substantial part of chromosome 20q, indicating that multiple genes on the 20q amplicon may drive carcinogenesis. The aim of this study was to identify genes located on the 20q amplicon that promote progression of colorectal adenoma to carcinoma. Design Functional assays were performed for 32 candidate driver genes for which a positive correlation between 20q DNA copy number and mRNA expression had been demonstrated. Effects of gene knockdown on cell viability, anchorage-independent growth, and invasion were analysed in colorectal cancer cell lines with 20q gain. Colorectal tumour protein expression was examined by immunohistochemical staining of tissue microarrays. Results TPX2, AURKA, CSE1L, DIDO1, HM13, TCFL5, SLC17A9, RBM39 and PRPF6 affected cell viability and/or anchorage-independent growth. Chromosome 20q DNA copy number status correlated significantly with TPX2 and AURKA protein levels in a series of colorectal adenomas and carcinomas. Moreover, downmodulation of TPX2 and AURKA was shown to inhibit invasion. Conclusion These data identify TPX2 (20q11) and AURKA (20q13.2) as two genes located on distinct regions of chromosome 20q that promote 20q amplicon-driven progression of colorectal adenoma to carcinoma. Therefore the selection advantage imposed by 20q gain in tumour progression is achieved by gain-of-function of multiple cancer-related genes—knowledge that can be translated into novel tests for early diagnosis of progressive adenomas.